In the future, the development of China's vaccine industry will present three major trends

[pharmaceutical network market analysis 】The vaccine industry belongs to the pharmaceutical industry, which is a fine molecule industry in the pharmaceutical industry It has the basic characteristics of the pharmaceutical industry, and its basic starting point is "health prevention health" Based on this starting point, the vaccine industry has a distinctive "end-to-end" industry characteristics, that is, based on the purpose of human health, the application of modern preventive medicine, biotechnology and other methods to produce products In fact, it is an industry that can reduce diseases, prevent diseases and keep human health as much as possible At present, based on the good development of global vaccine market, China's vaccine industry is also ushering in a period of rapid development What are the specific development trends? The industry will continue to develop steadily In recent years, with the strong support of national policies for the vaccine industry, the growth of residents' disposable income and the growing awareness of disease prevention, the increasing investment in vaccine research and development and production, and the gradual upgrading of products, the domestic vaccine industry is growing rapidly According to some data, since 2013, China's vaccination market has maintained an overall stable growth trend, with a market size of 27.6 billion yuan in 2018, 31.1 billion yuan in 2019 and 100.9 billion yuan in 2030 In fact, China has become a world leader in the production of human vaccines The annual number of vaccine batches issued is between 700 million and 1 billion, ranking first in the world Although in 2018, due to the long-lived biological events in China, the number of vaccine batches issued decreased significantly year-on-year, but with the decline of the impact of industrial events, the number of domestic vaccine batches issued is gradually returning to normal level However, it also led to the strict supervision of the vaccine industry in China, and continued to increase the strength of batch inspection and on-site inspection The introduction of the vaccine management law and the state's agreement to establish the inter ministerial joint meeting system of vaccine management not only mean the arrival of the era of strong vaccine supervision, but also will promote the acceleration of brand shuffling of the vaccine industry in the future At present, there are dozens of domestic vaccine enterprises, but compared with the concentration of global vaccine market, the concentration of domestic vaccine industry is relatively scattered In the future, from the perspective of segmented products, some small vaccine manufacturers, which have been on the market for a long time and have serious homogeneity, such as Hib vaccine, influenza vaccine, AC polysaccharide vaccine, rabies vaccine and other related manufacturers, will gradually stop issuing or be eliminated as the industry regulation becomes stricter The industry concentration will continue to improve, leading enterprises will benefit significantly in the future Summary from the whole point of view, whether vaccine enterprises have monopoly technology and can seize the market ahead of time determines the ability of sustainable development and excess profits In order to cope with the rapid changes in scientific and technological innovation and the increasingly fierce competition in international science and technology, international large-scale multinational vaccine enterprises are scrambling to increase investment in scientific research With reference to the development experience of International Vaccine enterprises, China's vaccine enterprises also attach great importance to R & D investment, technological innovation and new product R & D, and the state also supports vaccine enterprises to increase R & D investment In this environment, the future development of domestic vaccine industry will be further improved and ushered in the golden development period.